Market Access, Reimbursement & Health Economics Manager

About SkinVision

SkinVision is a CE-marked (Class IIa) AI-powered skin cancer risk assessment service, used by millions of people worldwide and recently recognised in the Top 250 Fastest Growing Companies in the Netherlands (Tech & Digital). We work with health insurers, healthcare providers and partners across Europe, the UK and Australia to detect skin cancer at the earliest, most treatable stage.

As we broaden how our service reaches patients and healthcare professionals, sustainable reimbursement becomes the foundation of our growth strategy, and we believe market access work must precede product launch, not follow it.

Market Access, Reimbursement & Health Economics Manager at SkinVision:

You will build and own SkinVision's reimbursement and market access roadmap, starting with the Netherlands as first priority, followed by the UK and broader EU markets. You will set up the market access, reimbursement and health economics function from the ground up — this calls for a hands-on, entrepreneurial mindset. You set the framework, prioritise markets, and drive payer engagement directly, supported by local consultants, KOLs and in-market partners where needed.

You will report to the Head of Clinical & Regulatory Affairs – QA, and work daily with Clinical, Regulatory, Commercial and Product teams.

What you will do

• Define, maintain and execute the reimbursement roadmap across current and future product lines, initially focus on the Netherlands and later UK and broader EU, including country prioritisation and entry sequencing

• Build and maintain a reimbursement intelligence base: funding routes, codes, tariffs, policy developments, gaps and risks per market

• Develop value dossiers and economic value propositions that translate our clinical evidence and real-world data into payer-relevant terms

• Own and further develop our health economics capability: build and maintain cost-effectiveness and budget-impact models, and present them in the form each payer system expects

• Partner with Clinical and Regulatory teams to align evidence generation (PMCF studies, health-economic analyses, claims-data studies) with payer and HTA requirements, so evidence gaps are closed before submissions, not after

• Lead and support engagement and negotiations with public and private payers — national health insurers, sickness funds — and with HTA and appraisal bodies (e.g. Zorginstituut Nederland, RIZIV/INAMI, NICE)

• Monitor reimbursement policy for digital health and AI-based SaMD (e.g. NL funding routes for digital care, Belgian mHealth pathways, NHS frameworks such as DTAC and the NICE Evidence Standards Framework) and identify openings for new codes, valuations or accelerated access

• Develop KOL and stakeholder engagement strategies that support access objectives, in coordination with Clinical Affairs

• Provide market access input into business cases, pricing strategy, partnership proposals (insurers, healthcare providers) and board-level decision-making